ATE294571T1 - Echinocandin pharmazeutische zusammensetzungen - Google Patents

Echinocandin pharmazeutische zusammensetzungen

Info

Publication number
ATE294571T1
ATE294571T1 AT00910391T AT00910391T ATE294571T1 AT E294571 T1 ATE294571 T1 AT E294571T1 AT 00910391 T AT00910391 T AT 00910391T AT 00910391 T AT00910391 T AT 00910391T AT E294571 T1 ATE294571 T1 AT E294571T1
Authority
AT
Austria
Prior art keywords
echinocandin
formulations
pharmaceutical compositions
freeze
solution
Prior art date
Application number
AT00910391T
Other languages
English (en)
Inventor
Nathaniel Milton
Kenneth Philip Moder
James Lawrence Sabatowski
Stephanie Ann Sweetana
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22403808&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE294571(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE294571T1 publication Critical patent/ATE294571T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT00910391T 1999-03-03 2000-03-02 Echinocandin pharmazeutische zusammensetzungen ATE294571T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12262399P 1999-03-03 1999-03-03
PCT/US2000/005546 WO2000051564A1 (en) 1999-03-03 2000-03-02 Echinocandin pharmaceutical formulations containing micelle-forming surfactants

Publications (1)

Publication Number Publication Date
ATE294571T1 true ATE294571T1 (de) 2005-05-15

Family

ID=22403808

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00910391T ATE294571T1 (de) 1999-03-03 2000-03-02 Echinocandin pharmazeutische zusammensetzungen

Country Status (19)

Country Link
US (2) US6960564B2 (de)
EP (2) EP1156782B1 (de)
JP (2) JP4936595B2 (de)
KR (1) KR100613136B1 (de)
CN (1) CN100335122C (de)
AT (1) ATE294571T1 (de)
AU (1) AU776782C (de)
BR (1) BRPI0009249B8 (de)
CA (1) CA2362481C (de)
CY (2) CY1114631T1 (de)
DE (1) DE60019902D1 (de)
DK (1) DK1582204T3 (de)
ES (1) ES2433678T3 (de)
HK (1) HK1040062A1 (de)
IL (1) IL145185A0 (de)
PT (1) PT1582204E (de)
RU (1) RU2250763C2 (de)
WO (1) WO2000051564A1 (de)
ZA (1) ZA200108002B (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743777B1 (en) * 1992-03-19 2004-06-01 Eli Lilly And Company Cyclic peptide antifungal agents and process for preparation thereof
CA2353930A1 (en) 1998-12-09 2000-06-15 Eli Lilly And Company Purification of echinocandin cyclopeptide compounds
ATE294571T1 (de) * 1999-03-03 2005-05-15 Lilly Co Eli Echinocandin pharmazeutische zusammensetzungen
AU767956B2 (en) 1999-03-03 2003-11-27 Eli Lilly And Company Formation and anion-exchange of crystalline echinocandin ammonium salts
BR0008713A (pt) 1999-03-03 2001-12-26 Lilly Co Eli Processos para preparar formulações ecomposições farmacêuticas orais com ecb
ES2204548T3 (es) 1999-03-03 2004-05-01 Eli Lilly And Company Complejos de equinocandina/carbohidrato.
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
US20040253315A1 (en) * 2001-07-13 2004-12-16 Yasuaki Ogawa Lyophilizing composition of drug-encapsulating polymer micelle and method for preparation thereof
JP2003342168A (ja) * 2002-05-24 2003-12-03 Nano Career Kk 注射用薬物含有ポリマーミセル製剤の製造方法
US6991800B2 (en) 2002-06-13 2006-01-31 Vicuron Pharmaceuticals Inc. Antifungal parenteral products
US7754230B2 (en) * 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
MXPA06013437A (es) * 2004-05-19 2007-03-23 Los Angeles Biomed Res Inst Uso de un detergente para la eliminacion no quirurgica de grasa.
CN100579510C (zh) * 2006-04-13 2010-01-13 新疆维吾尔自治区包虫病临床研究所 新型前体胶束制剂及其生产方法
US20100137197A1 (en) * 2007-06-26 2010-06-03 Sachin Mittal Lyophilized anti-fungal composition
US20090238867A1 (en) * 2007-12-13 2009-09-24 Scott Jenkins Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
CN102026621A (zh) 2008-05-15 2011-04-20 巴克斯特国际公司 稳定的药物制剂
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
US20130058965A1 (en) * 2009-12-31 2013-03-07 Mannkind Corporation Injectable formulations for parenteral administration
CN102618606B (zh) * 2011-01-30 2014-09-10 浙江海正药业股份有限公司 一种棘白菌素生物转化方法
CN102614492B (zh) * 2011-01-31 2013-12-11 上海天伟生物制药有限公司 一种含有棘白菌素类抗真菌剂米卡芬净的液体药用组合物
MX363465B (es) 2011-02-18 2019-03-25 Kythera Biopharmaceuticals Inc Tratamiento de la grasa submental.
HRP20171579T8 (hr) 2011-03-03 2018-12-14 Cidara Therapeutics, Inc. Antigljivična sredstva i njihova upotreba
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
CN102488889B (zh) * 2011-09-26 2014-01-22 上海天伟生物制药有限公司 一种低杂质含量的卡泊芬净制剂及其制备方法和用途
CN102488886B (zh) * 2011-09-26 2014-03-26 上海天伟生物制药有限公司 一种低杂质含量的卡泊芬净制剂及其制备方法和用途
EP2802340B1 (de) * 2012-01-12 2020-10-28 Celgene Corporation Romidepsinformulierungen und ihre verwendungen
CN104507309B (zh) * 2012-03-19 2017-05-03 奇达拉治疗公司 用于棘白菌素类化合物的给药方案
CN103570530B (zh) * 2012-07-26 2016-08-10 鲁南新时代生物技术有限公司 一种阿尼芬净侧链中间体的制备方法
CA2961029A1 (en) * 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
WO2016079749A2 (en) * 2014-11-19 2016-05-26 Gufic Biosciences Limited Process for preparation of parenteral formulation of anidulafungin
CN105641678A (zh) * 2014-12-03 2016-06-08 博瑞生物医药（苏州）股份有限公司 阿尼芬净胃肠外制剂及制备方法
EP3058958B1 (de) 2015-02-23 2018-09-19 Selectchemie AG Anidulafunginzusammensetzung
GR1008818B (el) * 2015-05-22 2016-08-01 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα εχινοκανδινης και μεθοδος παρασκευης αυτου
EP4647070A3 (de) * 2015-08-28 2026-01-21 Caliway Biopharmaceuticals Co. Ltd. Pharmazeutische zusammensetzung zur reduzierung von lokalem fett und verwendungen davon
US11318110B2 (en) 2015-08-28 2022-05-03 Caliway Biopharmaceuticals Co., Ltd. Pharmaceutical composition for reducing local fat and uses thereof
WO2017037232A1 (en) * 2015-09-02 2017-03-09 Xellia Pharmaceuticals Aps Anidulafungin formulations
JP7224916B2 (ja) 2016-03-16 2023-02-20 シダラ セラピューティクス インコーポレーテッド 真菌感染の処置のための投薬レジメン
CA3069423C (en) 2017-07-12 2025-04-15 Napp Pharmaceutical Group Limited Formulations for the treatment of fungal infections
CN109574811B (zh) * 2018-11-22 2021-12-24 中山大学 一种阿尼芬净侧链中间体对戊氧基三联苯甲酸的制备方法
CN109481665B (zh) * 2018-12-05 2019-08-06 广州迈达康医药科技有限公司 一种注射用阿尼芬净复溶药剂及其制备方法
EP4057992A4 (de) 2019-11-22 2024-10-16 Leiutis Pharmaceuticals LLP Stabile parenterale formulierungen von duloxetin
JP2025535828A (ja) 2022-10-25 2025-10-28 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 エキノカンジン類似体の医薬組成物及びその調製方法

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2002A (en) * 1841-03-12 Tor and planter for plowing
US3293482A (en) * 1962-06-21 1966-12-20 Rca Corp Plural output traveling wave tube
JPS5134916B2 (de) * 1974-03-06 1976-09-29
JPS5668616A (en) * 1979-11-08 1981-06-09 Yukio Kimura Preparation of antibiotic composition
US4293489A (en) * 1979-12-13 1981-10-06 Eli Lilly And Company Derivatives of A-30912A nucleus
US4299763A (en) * 1979-12-13 1981-11-10 Eli Lilly And Company A-30912B Nucleus
US4293482A (en) * 1979-12-13 1981-10-06 Eli Lilly And Company A-30912A Nucleus
US4293483A (en) * 1979-12-13 1981-10-06 Eli Lilly And Company Derivatives of A-30912A nucleus
CA1170598A (en) 1979-12-13 1984-07-10 Bernard J. Abbott Process for the preparation of cyclic peptide nuclei
CA1183127A (en) 1979-12-13 1985-02-26 Manuel Debono Process for the preparation of derivatives of cyclic peptide nuclei
US4320052A (en) * 1979-12-13 1982-03-16 Eli Lilly And Company Derivatives of A-30912A nucleus
US4304716A (en) * 1979-12-13 1981-12-08 Eli Lilly And Company S 31794/F-1 Nucleus
US4348384A (en) * 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
US5141674A (en) * 1984-03-08 1992-08-25 Phares Pharmaceutical Research N.V. Methods of preparing pro-liposome dispersions and aerosols
US4876241A (en) * 1987-05-22 1989-10-24 Armour Pharmaceutical Company Stabilization of biological and pharmaceutical products during thermal inactivation of viral and bacterial contaminants
US5000000A (en) * 1988-08-31 1991-03-19 University Of Florida Ethanol production by Escherichia coli strains co-expressing Zymomonas PDC and ADH genes
DK173802B1 (da) 1988-09-12 2001-11-05 Merck & Co Inc Præparat til behandling af Pneumocystis carinii infeksioner og anvendelse af et cyclohexapeptid til fremstilling af et lægemiddel mod Pneumocystis carinii infektioner
US5166135A (en) * 1988-09-12 1992-11-24 Merck & Company, Inc. Method for the control of pneumocystis carinii
AU617541B2 (en) 1988-10-20 1991-11-28 Wyeth Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors
US4927831A (en) * 1988-10-20 1990-05-22 American Home Products Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors
CA2011365A1 (en) * 1989-03-06 1990-09-06 Eugene L. Inman Diluent formulation for daptomycin
US5202309A (en) * 1989-06-30 1993-04-13 Merck & Co., Inc. Antibiotic cyclopeptide fermentation product
JP2844351B2 (ja) * 1989-07-13 1999-01-06 株式会社科薬 安定なポリミキシン系抗生物質水性溶液
JPH03240727A (ja) * 1990-02-15 1991-10-28 Toyo Jozo Co Ltd ニューモシスチス・カリニ肺炎治療剤
CA2037957A1 (en) 1990-03-12 1991-09-13 Merck & Co., Inc. N-acylated cyclohexapeptide compounds
GB2241956A (en) 1990-03-16 1991-09-18 Merck & Co Inc N-acylated cyclohexapeptide compounds
IL97347A0 (en) 1990-03-19 1992-05-25 Merck & Co Inc Lipopeptide derivatives and antimicrobial compositions containing them
IE910892A1 (en) 1990-03-19 1991-09-25 Merck & Co Inc Lipopeptide compounds
US5386009A (en) 1990-03-19 1995-01-31 Merck & Co. Inc. Lipopeptide derivatives
US5330973A (en) 1990-03-19 1994-07-19 Merck & Co., Inc. Lipopeptide derivatives
US5049546A (en) 1990-03-19 1991-09-17 Merck & Co., Inc. Antibiotic agents
US5310726A (en) 1990-03-19 1994-05-10 Merck & Co., Inc. Lipopeptide compounds
CA2043762C (en) 1990-06-07 2001-05-29 Adam J. Kreuzman Lipopeptide deacylase
IL98506A (en) 1990-06-18 1996-09-12 Fujisawa Pharmaceutical Co Cyclic peptide antibiotics processes for the preparation thereof and pharmaceutical compositions containing them
US5198421A (en) * 1991-04-26 1993-03-30 Merck & Co., Inc. Phosphorylated cyclic lipopeptide
EP0486011A3 (en) 1990-11-16 1992-07-15 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical composition against pneumocystis carinii
US5369093A (en) 1991-03-15 1994-11-29 Merck & Co., Inc. Lipopeptide derivatives
US5993805A (en) * 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
US5136783A (en) * 1991-05-23 1992-08-11 Blount, Inc. Chain saw sprocket
US5233023A (en) 1991-07-30 1993-08-03 Merck & Co., Inc. Process for phosphate ester compounds of certain cyclohexapeptides
JPH05271097A (ja) * 1991-10-07 1993-10-19 Asahi Chem Ind Co Ltd アクレアシン類の可溶化剤および医薬組成物
MY136593A (en) * 1992-03-19 2008-10-31 Lilly Co Eli Cyclic peptide antifungal agents and process for preparation thereof
US6743777B1 (en) * 1992-03-19 2004-06-01 Eli Lilly And Company Cyclic peptide antifungal agents and process for preparation thereof
US5965525A (en) * 1992-03-19 1999-10-12 Eli Lilly And Company Cyclic peptide antifungal agents
US6384013B1 (en) * 1992-03-19 2002-05-07 Eli Lilly And Company Cyclic peptide antifungal agents and process for preparation thereof
EP0589074B1 (de) 1992-09-22 2001-11-21 Takeo Dr. Takayanagi Kohlenhydrate-Komplexe zur Vernichtung von Krebszellen
ES2079994B1 (es) * 1992-10-07 1996-08-01 Cusi Lab Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica.
JPH06172205A (ja) * 1992-12-11 1994-06-21 Asahi Chem Ind Co Ltd アクレアシン類含有脂肪乳剤
US6268338B1 (en) * 1993-04-30 2001-07-31 Merck & Co., Inc. Cyclohexapeptidyl amine compounds
AU674233B2 (en) * 1993-05-04 1996-12-12 Merck & Co., Inc. Cyclohexapeptidyl aminoalkyl ethers
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US5541160A (en) * 1994-04-04 1996-07-30 Merck & Co., Inc. Antifungal and anti-pneumocystis compounds, compositions containing such compounds, and methods of use
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US5646111A (en) * 1995-04-07 1997-07-08 Eli Lilly And Company Cyclic peptide antifungal Agents
US5629290A (en) 1995-05-26 1997-05-13 Eli Lilly And Company Cyclic peptide antifungal agents
US5618787A (en) * 1995-05-26 1997-04-08 Eli Lilly And Company Cyclic peptide antifungal agents
US5652213A (en) * 1995-05-26 1997-07-29 Eli Lilly And Company Cyclic peptide antifungal agents
US5786325A (en) * 1995-05-26 1998-07-28 Eli Lilly And Company Cyclic peptide antifungal agents and methods of making and using
GB9515182D0 (en) * 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
US5629289A (en) 1995-07-25 1997-05-13 Eli Lilly And Company Cyclic peptide antifungal agents
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
FR2740686B1 (fr) * 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
AU1851797A (en) 1996-02-01 1997-08-22 Eli Lilly And Company Cyclic peptide antifungal agents
US5693611A (en) * 1996-02-01 1997-12-02 Eli Lilly And Company Cyclic peptide antifungal agents
US6245349B1 (en) * 1996-02-23 2001-06-12 éLAN CORPORATION PLC Drug delivery compositions suitable for intravenous injection
PE63998A1 (es) * 1996-04-19 1998-10-30 Merck & Co Inc Composiciones anti-fungosas
US5952300A (en) * 1996-04-19 1999-09-14 Merck & Co., Inc. Antifungal compositions
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5696084A (en) * 1996-08-16 1997-12-09 Abbott Laboratories Amino-lipopetide antifungal agents
FR2755857B1 (fr) * 1996-11-19 1998-12-24 Rhone Poulenc Rorer Sa Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation
AUPO381496A0 (en) * 1996-11-25 1996-12-19 Fujisawa Pharmaceutical Co., Ltd. New compound
US5985248A (en) * 1996-12-31 1999-11-16 Inhale Therapeutic Systems Processes for spray drying solutions of hydrophobic drugs and compositions thereof
AUPO691897A0 (en) * 1997-05-21 1997-06-12 Fujisawa Pharmaceutical Co., Ltd. New compound
CA2301184A1 (en) * 1997-08-04 1999-02-11 Eli Lilly And Company Cyclic peptide antifungal agents
US5972996A (en) * 1997-08-22 1999-10-26 Merck & Co., Inc. 4-cyano-4-deformylsordarin derivatives
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
EP0931834A3 (de) 1997-12-23 2002-06-26 Eli Lilly And Company Echinocandin-bindungsdomäne von 1,3-Beta-glukan Synthase
US6323176B1 (en) * 1998-02-25 2001-11-27 Eli Lilly And Company Cyclic peptide antifungal agents
US6284282B1 (en) * 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
US6423345B2 (en) * 1998-04-30 2002-07-23 Acusphere, Inc. Matrices formed of polymer and hydrophobic compounds for use in drug delivery
US6451349B1 (en) * 1998-08-19 2002-09-17 Quadrant Healthcare (Uk) Limited Spray-drying process for the preparation of microparticles
EP1107981B1 (de) 1998-08-20 2005-01-26 Eli Lilly & Company Verfahren zur herstellung von ring-modifizierten zyklischen peptidanalogen
WO2000012540A1 (en) 1998-08-28 2000-03-09 Eli Lilly And Company Reversible boronate complexes of 1,2-cis-diol cyclic-peptides
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
CA2353930A1 (en) 1998-12-09 2000-06-15 Eli Lilly And Company Purification of echinocandin cyclopeptide compounds
AU767357B2 (en) 1998-12-16 2003-11-06 Eli Lilly And Company Cyclic peptide antifungal agents
AU2189500A (en) 1998-12-16 2000-07-03 Eli Lilly And Company Cyclic peptide antifungal agents having a sugar substituent
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
AU767956B2 (en) 1999-03-03 2003-11-27 Eli Lilly And Company Formation and anion-exchange of crystalline echinocandin ammonium salts
ATE294571T1 (de) * 1999-03-03 2005-05-15 Lilly Co Eli Echinocandin pharmazeutische zusammensetzungen
ES2204548T3 (es) 1999-03-03 2004-05-01 Eli Lilly And Company Complejos de equinocandina/carbohidrato.
BR0008713A (pt) 1999-03-03 2001-12-26 Lilly Co Eli Processos para preparar formulações ecomposições farmacêuticas orais com ecb
US6258821B1 (en) * 1999-04-26 2001-07-10 Medimmune Oncology, Inc. Compositions comprising trimetrexate and methods of their synthesis and use
WO2003018051A1 (en) * 2001-08-27 2003-03-06 Vic Jira Anti-fungal composition
US6991800B2 (en) * 2002-06-13 2006-01-31 Vicuron Pharmaceuticals Inc. Antifungal parenteral products

Also Published As

Publication number Publication date
EP1582204A3 (de) 2007-10-10
ZA200108002B (en) 2003-06-25
WO2000051564A1 (en) 2000-09-08
CA2362481C (en) 2008-11-04
DE60019902D1 (de) 2005-06-09
RU2250763C2 (ru) 2005-04-27
EP1582204A2 (de) 2005-10-05
CY2014003I1 (el) 2015-12-09
BRPI0009249A (pt) 2001-11-20
ES2433678T3 (es) 2013-12-12
EP1156782B1 (de) 2005-05-04
CN100335122C (zh) 2007-09-05
EP1156782A1 (de) 2001-11-28
PT1582204E (pt) 2013-11-25
KR20010111570A (ko) 2001-12-19
US20050192213A1 (en) 2005-09-01
IL145185A0 (en) 2002-06-30
KR100613136B1 (ko) 2006-08-17
BRPI0009249B8 (pt) 2021-07-06
AU3249100A (en) 2000-09-21
CY2014003I2 (el) 2015-12-09
US7709444B2 (en) 2010-05-04
CY1114631T1 (el) 2015-12-09
WO2000051564A8 (en) 2002-05-30
CA2362481A1 (en) 2000-09-08
HK1040062A1 (zh) 2002-05-24
US20030054981A1 (en) 2003-03-20
JP4755464B2 (ja) 2011-08-24
US6960564B2 (en) 2005-11-01
HK1074803A1 (en) 2005-11-25
BRPI0009249B1 (pt) 2011-11-29
CN1345229A (zh) 2002-04-17
JP2005325142A (ja) 2005-11-24
DK1582204T3 (da) 2013-11-04
EP1582204B1 (de) 2013-09-25
AU776782B2 (en) 2004-09-23
AU776782C (en) 2005-04-07
JP4936595B2 (ja) 2012-05-23
JP2002538095A (ja) 2002-11-12

Similar Documents

Publication Publication Date Title
ATE294571T1 (de) Echinocandin pharmazeutische zusammensetzungen
ECSP045496A (es) "preparaciones acidas de insulina con estabilidad mejorada"
EA200501001A1 (ru) Фармацевтический состав с нерастворимым активным агентом
NO994409D0 (no) Stabilisering av syresensitive benzimidazoler med aminosyre/cyklodekstrin-kombinasjoner
PE20020968A1 (es) Preparados de insulina exentos de zinc y pobres en zinc, con estabilidad mejorada
AR043863A1 (es) Composiciones que contienen piperacilina y tazobactam, utiles para inyeccioines
DE69418468D1 (de) Viskoelastische zusammensetzungen aus organischen fluorierten verbindungen
WO2001064187A8 (en) Anaesthetic formulations
NO307326B1 (no) Lipofile, oligosakkaride antibiotikasaltpreparater
DK1157030T3 (da) Enchinocanidin/carbohydratkomplekser
DK1280558T3 (da) Halvfast indgivelsesvehikel og farmaceutiske sammensætninger
KR970705978A (ko) 가역성열겔화 수용성 의약 조성물을 함유하는 동결건조 제제(Lyophilized pharmaceutical preparations capable of providing aqueous drug composition having property of reversible thermosetting gelation)
AR039388A1 (es) Formulaciones liquidas de baja dosis de entecavir y uso
BRPI0418115A (pt) formulação lìquida estável de hormÈnio de crescimento
AR014772A1 (es) Una formulacion acuosa que permite la estabilizacion de conjugados de peg-interferon alfa durante y despues de la liofilizacion, proceso para producir un polvo liofilizado, un polvo liofilizado, un proceso para producir una solucion de los conjudados peg-interferon-alfa y un articulo de manufactura
ATE367165T1 (de) Xanthangummi enthaltende reepithelialisierende pharmazeutische zubereitungen
MX9400801A (es) Agentes colinergicos de oxima de tetrahidropiridinna o-substituidos estabilizados con almidon.
HRP20050342B1 (hr) Farmaceutska formulacija olanzapina
AU3548901A (en) Veterinary compositions for the treatment of parasitic diseases
MY110074A (en) Pharmacuetical formulation.
AR044697A1 (es) Formulaciones farmaceuticas que comprenden amoxicilina y clavulanato
RU2001100069A (ru) Антгельминтное средство
BR0108732A (pt) Composição farmacêutica para a prevenção e tratamento da progressão da fibrose e cirrose hepática, seu uso e método para a prevenção e tratamento da fibrose e cirrose hepática
ES2118033B1 (es) Formulacion farmaceutica antiinflamatoria.
ECSP982396A (es) Composiciones que contienen tetrahidrolipstatina